Your browser doesn't support javascript.
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.
Chi, Xiangyang; Guo, Yingying; Zhang, Guanying; Sun, Hancong; Zhang, Jun; Li, Min; Chen, Zhengshan; Han, Jin; Zhang, Yuanyuan; Zhang, Xinghai; Fan, Pengfei; Zhang, Zhe; Wang, Busen; Zai, Xiaodong; Han, Xuelian; Hao, Meng; Fang, Ting; Xu, Jinghan; Wu, Shipo; Chen, Yi; Fang, Yingying; Dong, Yunzhu; Sun, Bingjie; Zhang, Jinlong; Li, Jianmin; Zhao, Guangyu; Yu, Changming; Zhou, Qiang; Chen, Wei.
  • Chi X; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Guo Y; Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou, 310024, Zhejiang Province, Chi
  • Zhang G; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Sun H; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Zhang J; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Li M; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Chen Z; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Han J; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Zhang Y; Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou, 310024, Zhejiang Province, Chi
  • Zhang X; Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
  • Fan P; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Zhang Z; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Wang B; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Zai X; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Han X; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Hao M; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Fang T; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Xu J; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Wu S; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Chen Y; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Fang Y; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Dong Y; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Sun B; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Zhang J; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Li J; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China.
  • Zhao G; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China. guangyu0525@outlook.com.
  • Yu C; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China. yuchangming@126.com.
  • Zhou Q; Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, Institute of Biology, Westlake Institute for Advanced Study, School of Life Sciences, Westlake University, Hangzhou, 310024, Zhejiang Province, Chi
  • Chen W; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China. cw0226@foxmail.com.
Signal Transduct Target Ther ; 7(1): 139, 2022 04 27.
Article in English | MEDLINE | ID: covidwho-1815514
ABSTRACT
The SARS-CoV-2 Omicron variant shows substantial resistance to neutralization by infection- and vaccination-induced antibodies, highlighting the demands for research on the continuing discovery of broadly neutralizing antibodies (bnAbs). Here, we developed a panel of bnAbs against Omicron and other variants of concern (VOCs) elicited by vaccination of adenovirus-vectored COVID-19 vaccine (Ad5-nCoV). We also investigated the human longitudinal antibody responses following vaccination and demonstrated how the bnAbs evolved over time. A monoclonal antibody (mAb), named ZWD12, exhibited potent and broad neutralization against SARS-CoV-2 variants Alpha, Beta, Gamma, Kappa, Delta, and Omicron by blocking the spike protein binding to the angiotensin-converting enzyme 2 (ACE2) and provided complete protection in the challenged prophylactic and therapeutic K18-hACE2 transgenic mouse model. We defined the ZWD12 epitope by determining its structure in complex with the spike (S) protein via cryo-electron microscopy. This study affords the potential to develop broadly therapeutic mAb drugs and suggests that the RBD epitope bound by ZWD12 is a rational target for the design of a broad spectrum of vaccines.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Signal Transduct Target Ther Year: 2022 Document Type: Article Affiliation country: S41392-022-00987-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Signal Transduct Target Ther Year: 2022 Document Type: Article Affiliation country: S41392-022-00987-z